Akyso Therapeutics

Executive Summary

Akyso Therapeutics is a private biotechnology company headquartered in Cambridge, MA, developing a novel bioabsorbable drug delivery platform called iSTEP. The platform enables sustained release of therapeutics from a single subcutaneous implant for six to twelve months, offering a transformative approach to chronic disease management. The company's lead candidate is a naltrexone implant for opioid use disorder (OUD), currently in Phase 3 clinical trials. If approved, this long-acting formulation could significantly improve patient adherence and reduce the risk of relapse, addressing a critical unmet need in the opioid epidemic. Akyso's technology has the potential to be extended to other therapeutic areas, including addiction medicine and beyond. As a Phase 3 company with a clear and compelling value proposition, Akyso is positioned for near-term value inflection. The iSTEP platform differentiates itself through its bioabsorbable nature, eliminating the need for device removal. Positive Phase 3 data would pave the way for regulatory submission and potential commercialization, either independently or via a strategic partnership. The company's focus on a high-burden indication with strong societal need may also attract non-dilutive funding and favorable regulatory pathways. With a proprietary platform and advancing pipeline, Akyso represents a promising investment opportunity in the drug delivery space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Topline Data for Naltrexone Implant in Opioid Use Disorder60% success
• Q2 2026FDA Type C Meeting or Breakthrough Therapy Designation40% success
• Q1 2027Strategic Partnership or Licensing Deal for Commercialization50% success